M. Williams

发表

Von Willebrand disease: diagnosis and management

M. Williams, Jesal Patel, 2015, Paediatrics and Child Health.

Requirement of VPS 33 B , a member of the Sec 1 / Munc 18 protein family , in megakaryocyte and platelet-granule biogenesis

D. Chitayat, P. Gissen, W. Kahr, 2005 .

The haematological investigation of suspected Non Accidental Injury

J. Lancashire, M. Williams, 2017 .

Distinguishing between type 2B and pseudo‐von Willebrand disease and its clinical importance

F. Hill, A. Guilliatt, J. Wilde, 2006, British journal of haematology.

Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis.

D. Chitayat, P. Gissen, W. Kahr, 2005, Blood.

Thrombolysis in children

M. Williams, 2010, British journal of haematology.

Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A.

F. Hill, B. Theophilus, M. S. Enayat, 2001 .

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non‐A, non‐B hepatitis

K. Pasi, F. Hill, S. Mawson, 1990, Journal of medical virology.

The investigation and management of neonatal haemostasis and thrombosis *

E. Chalmers, B. Gibson, M. Williams, 2002, British journal of haematology.

binding in a patient with a bleeding diathesis receptor D304N variant that abrogates ligand 2 A novel thromboxane A

S. Mundell, S. Watson, M. Wheatley, 2010 .

A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

R. Liesner, P. Collins, J. Hanley, 2010, British journal of haematology.

Guideline on the management of haemophilia in the fetus and neonate *

R. Liesner, P. Collins, E. Chalmers, 2011, British journal of haematology.

A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO

S. Watson, D. Perry, A. Mumford, 2006, British journal of haematology.

Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A

D. Stirling, R. Liesner, Angela E. Thomas, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

M. Makris, R. Liesner, D. Hart, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

F. Kamali, L. Brandão, E. Chalmers, 2012, Blood.

A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis.

S. Mundell, S. Watson, M. Wheatley, 2010, Blood.

large proportion of the variability in warfarin dose requirement among genotype and patient characteristics explain a CYP 2 C 9 and VKORC

F. Kamali, L. Brandão, J. Hanley, 2012 .

Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat‐treated factor VIII concentrate (BPL 8Y)

K. Pasi, F. Hill, M. Williams, 1990, British journal of haematology.

Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)

K. Pasi, F. Hill, J. A. Evans, 1991, British journal of haematology.

type 3 von Willebrand disease and predisposition to inhibitor development Homozygous gene conversion in von Willebrand factor gene as a cause of

F. Hill, S. Lawson, M. Williams, 2001 .

Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y

S. Machin, S. Allford, W. Lester, 2002, British journal of haematology.

Acquired Disorders of Hemostasis

Angela E. Thomas, E. Chalmers, M. Williams, 2007 .

Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease.

K. Pasi, F. Hill, M. D. Williams, 2001, Blood.